12/18
01:52 pm
atha
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript [Seeking Alpha]
Low
Report
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript [Seeking Alpha]
12/18
07:32 am
atha
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million [Yahoo! Finance]
Low
Report
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million [Yahoo! Finance]
12/18
07:02 am
atha
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
High
Report
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
11/6
04:05 pm
atha
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
10/24
12:16 pm
atha
Athira Pharma (NASDAQ:ATHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Athira Pharma (NASDAQ:ATHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.